Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jns.2014.07.006 http://scihub22266oqcxt.onion/10.1016/j.jns.2014.07.006 C4177939!4177939!25060418     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Neurol+Sci 2014 ; 345 (ä): 61-7 Nephropedia Template TP {{tp|p=25060418|t=2014. A Dose Response Study of Thymosin ?4 for the Treatment of Acute Stroke |pdf=|usr=}}{{25060418}} gab.com Text A Dose Response Study of Thymosin 4 for the Treatment of Acute Stroke JO: J Neurol Sci http://www.kidney.de/pget.php?&tw=1&pmid=25060418 #FOAvip Background: Thymosin ?4 (T?4) is a 5K actin binding peptide. T?4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this study was to perform a dose response study of T?4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. Methods: Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. T?4 was administered intraperitoneally 24 hrs after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized Estimating Equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. Results: T?4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values<0.05). The higher dose of 18 mg/kg did not show significant improvement. The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement. Conclusions: This study showed that T?4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials. Twit Text FOAVip A Dose Response Study of Thymosin 4 for the Treatment of Acute Stroke ????J Neurol Sci http://www.kidney.de/pget.php?&tw=1&pmid=25060418 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25060418 #FOAvip English Wikipedia <ref>{{Cite pmid|25060418}}</ref> A Dose Response Study of Thymosin ?4 for the Treatment of Acute Stroke #MMPMID25060418 Morris DC; Cui Y; Cheung WL; Lu M; Zhang L; Zhang ZG; Chopp M J Neurol Sci 2014[Oct]; 345 (ä): 61-7 PMID25060418show ga Background: Thymosin ?4 (T?4) is a 5K actin binding peptide. T?4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this study was to perform a dose response study of T?4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. Methods: Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2, 12 and 18 mg/kg. T?4 was administered intraperitoneally 24 hrs after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized Estimating Equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. Results: T?4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values<0.05). The higher dose of 18 mg/kg did not show significant improvement. The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement. Conclusions: This study showed that T?4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials. äA Dose Response Study of Thymosin ?4 for the Treatment of Acute Stroke(epmc).pdf DeepDyve Pubget Overpricing